Do You Know JAK? New Insights on JAK Inhibition in RA
PROGRAM DESCRIPTION Rheumatoid arthritis (RA) is the most common inflammatory arthritis in adults. Janus kinases (JAKs) are central to the destructive immune and inflammatory responses implicated in the pathogenesis of …
Rheumatoid arthritis (RA) is the most common inflammatory arthritis in adults. Janus kinases (JAKs) are central to the destructive immune and inflammatory responses implicated in the pathogenesis of RA. In this activity, the expert faculty, Dr. Roy Fleischmann, Dr. Allan Gibofsky and Dr. Joseph Markenson, will provide a primer on the role of JAKs in the pathophysiology of RA and the clinical use of JAK inhibitors.You will have an opportunity to test your knowledge of JAKs, JAK inhibitors, and their use in the treatment of RA in the interactive “Do You Know JAK?” game. The object of the game is to successfully inhibit the progress of RA through correctly answering questions about the disease, the inflammatory pathways, and therapeutic options for treatment. Correct answers will result in successful JAK inhibition and reduction of inflammation, while incorrect answers will show no change. These exercises will be followed by a roundtable discussion with the faculty highlighting the unique features of JAK inhibition in RA.
Upon proper completion of this activity, participants should be better able to:Describe the role of Janus kinase (JAK) in the chronic cycle of inflammation associated with RAIdentify the intracellular immune and anti-inflammatory effects of JAK inhibition on RASelect appropriate candidates for treatment of RA with JAK inhibitors
I'm interested in this
Share with others
Write the first review
Share with others